Holen Sie sich die Stockscreener-App
24.84
2.20%
-0.56
Handel nachbörslich:
25.34
0.50
+2.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.40
Offen:
$25.36
24-Stunden-Volumen:
661.65K
Relative Volume:
1.17
Marktkapitalisierung:
$1.62B
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-425.15M
KGV:
-2.7308
EPS:
-9.0964
Netto-Cashflow:
$-210.48M
1W Leistung:
-8.88%
1M Leistung:
-23.14%
6M Leistung:
+14.15%
1J Leistung:
+2.60%
1-Tages-Spanne:
$24.51
$25.96
1-Wochen-Bereich:
$24.25
$27.49
52-Wochen-Spanne:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
24.84 | 1.62B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease - GlobeNewswire Inc.
COVID vaccination produced immune responses in all 4 participants during a planned treatment break - Stock Titan
Zenas BioPharma (NasdaqGS:ZBIO) Stock Forecast & Analyst Predictions - Simply Wall Street
Zenas BioPharma Plunges As Dilution Fears Ignite Selloff - TipRanks
Zenas BioPharma (Nasdaq:ZBIO)Stock Analysis - Simply Wall Street
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma Grants Stock Options and RSUs to Newly Hired Employees as Inducement Awards - Quiver Quantitative
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New Zenas hires receive stock awards that vest over four years - Stock Titan
Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling StockholderSEC Filing - TradingView
Wellington Management Group LLP Adds 4,972,315 Shares of Zenas BioPharma Inc (ZBIO) - GuruFocus
ZBIO: Obexelimab nears FDA review with strong market potential and pivotal data readouts ahead - TradingView
Zenas BioPharma at Citi summit: pipeline bets and cash runway By Investing.com - Investing.com India
Zenas BioPharma at Citi summit: pipeline bets and cash runway By Investing.com - Investing.com Canada
Zenas BioPharma at Citi summit: pipeline bets and cash runway By Investing.com - Investing.com UK
A 10% slice of Zenas BioPharma (NASDAQ: ZBIO) sits with one investment group - Stock Titan
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - GlobeNewswire
InnoCare reports 10.4% passive Zenas BioPharma stake | ZBIO SEC FilingForm SCHEDULE 13G/A - Stock Titan
Zenas BioPharma (ZBIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - Yahoo Finance
Director at Zenas BioPharma (ZBIO) granted 37,000 options - Stock Titan
Enavate Sciences GP, LLC Reduces Zenas BioPharma Inc (ZBIO) Stak - GuruFocus
Zenas (ZBIO) Levels: Advances 2.12% to $32.29 in the Latest Reading; Levels: the Price Remains Bounded by the Supplied Support and Resistance at the CloseGap and Go - siam.in
Zenas (ZBIO) Levels: Advances 2.12% to $32.29 in the Latest Reading; Levels: the Price Remains Bounded by the Supplied Support and Resistance at the CloseTWAP Entry - vinanet.vn
Zenas BioPharma (ZBIO) Is Up 9.4% After Wider Losses And Board AdditionHas The Bull Case Changed? - simplywall.st
Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan
Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan
HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat
SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo
ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - vinanet.vn
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma grants inducement awards to new hires - scanx.trade
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Australia
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
May 18 '26 |
Buy |
16.88 |
60,000 |
1,012,800 |
96,928 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 29 '26 |
Buy |
17.62 |
35,000 |
616,700 |
1,786,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
5.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):